title: Capability of SART3(109-118) peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles.
abstract: We previously reported the SART3 gene to be a tumor-rejection antigen gene encoding a peptide at positions 109-118 (SART3(109-118)) with the ability to induce HLA-A24-restricted cytotoxic T lymphocytes. In this study, we investigated both humoral and cellular responses to this peptide in cancer patients with alleles other than HLA-A24 to explore the possibility of using this peptide as a cancer vaccine for these patients. IgG reactive to SART3(109-118) peptide was identified in sera of the vast majority of non-cancer subjects (n=50) and all cancer patients (n=50) tested without apparent HLA-A association. Levels of anti-SART3(109-118) peptide antibody in cancer patients were significantly higher than those of non-cancer subjects, but no difference was found between HLA-A24+A2- and HLA-A24-A2+ cancer patients. This peptide induced cancer cell-reactive cytotoxic T lymphocytes from peripheral blood mononuclear cells of both healthy donors and prostate cancer patients with HLA-A11, HLA-A31 and HLA-A33 alleles, but not with HLA-A2. These results suggest that this peptide can be applicable as a cancer vaccine not only for HLA-A24+, but also for HLA-A11+, HLA-A31+ and HLA-A33+ prostate cancer patients.
authors.affiliation: Department of Urology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
authors.forename: Elnisr Rashed
authors.initials: ER
authors.lastname: Mohamed
authors.forename: Masayasu
authors.initials: M
authors.lastname: Naito
authors.forename: Yasunobu
authors.initials: Y
authors.lastname: Terasaki
authors.forename: Yamei
authors.initials: Y
authors.lastname: Niu
authors.forename: Shojiro
authors.initials: S
authors.lastname: Gohara
authors.forename: Nobukazu
authors.initials: N
authors.lastname: Komatsu
authors.forename: Shigeki
authors.initials: S
authors.lastname: Shichijo
authors.forename: Kyogo
authors.initials: K
authors.lastname: Itoh
authors.forename: Masanori
authors.initials: M
authors.lastname: Noguchi
mesh_terms: D000199:Actins / Q000235:genetics; D000595:Amino Acid Sequence; D000951:Antigens, Neoplasm / Q000737:chemistry* / Q000502:physiology*; D045744:Cell Line, Tumor; D017931:DNA Primers; D015234:HLA-A Antigens / Q000235:genetics / Q000276:immunology; D015395:Histocompatibility Antigens Class I / Q000235:genetics*; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008297:Male; D010446:Peptide Fragments / Q000276:immunology* / Q000494:pharmacology; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000276:immunology*; D016601:RNA-Binding Proteins / Q000737:chemistry* / Q000502:physiology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
chemical_list: D000199:Actins; D000951:Antigens, Neoplasm; D017931:DNA Primers; D015234:HLA-A Antigens; D015395:Histocompatibility Antigens Class I; D007074:Immunoglobulin G; D010446:Peptide Fragments; D016601:RNA-Binding Proteins; C416530:SART3 protein, human